TCR MOA: Mechanism of Action Summary
Targeting the TCR: Biological Roles and Therapeutic Strategies
TRAV/TRBV
TRAC/TRBC
Strain specific TCR Vβ13.1 expression analysis in wild-type C57BL/6JNifdc mice and homozygous B-hTCR mice by flow cytometry. Blood cells were collected from wild-type C57BL/6JNifdc mice (+/+) and homozygous B-hTCR mice (H/H), and analyzed by flow cytometry with species-specific anti-mouse TCRVβ6 antibody (Biolegend, 140004) and anti-human TCR Vβ13.1 antibody (Biolegend, 362408).
Analysis of leukocyte subpopulations by flow cytometry in immune organs and blood. Splenocytes, peripheral blood, lymph nodes, and thymuses were isolated from C57BL/6JNifdc and B-hTCR mice (male, 10-week-old, n = 3). Single live cells were gated on the CD45⁺ population and analyzed by flow cytometry as indicated. Values are expressed as mean ± SEM.
Analysis of T-cell subpopulations by flow cytometry in immune organs and blood. Splenocytes, peripheral blood, lymph nodes, and thymuses were isolated from C57BL/6JNifdc and B-hTCR mice (male, 9-week-old, n = 3). Single live cells were gated on the CD3⁺ T-cell population and analyzed by flow cytometry as indicated. Values are expressed as mean ± SEM.
Establishment of an MC38 model and in vivo efficacy study of the Invikafusp alfa-analog. MC38 colon cancer cells were implanted subcutaneously into homozygous B-hTCR mice (male, 12-weeks-old, n = 6). When the average tumor volume reached approximately 88 mm³, mice were randomized and subsequently administered the Invikafusp alfa-analog (made in house) via intraperitoneal injection.
Efficacy of Invikafusp alfa-analog in B-hTCR mice. (A) Tumor growth curves. (B) Body weight changes during treatment. (C) Tumor cells growth of individual mouse. As shown in panel A, the Invikafusp alfa-analog (made in house) was efficacious in controlling tumor growth in B-hTCR mice, demonstrating that the B-hTCR mice provide a powerful preclinical model for in vivo evaluation of human TCR Vβ-targeted drugs. Values are expressed as mean ± SEM.
Invikafusp alfa-analog enhances beneficial repertoire of anti-tumor T cells. Tumors from MC38 tumor-bearing mice that were treated with the PBS or Invikafusp alfa-analog were analyzed on day 18. Analysis of NK cells, T cells, CD8+ T cells, CD4+ T cells, Tregs, and Granzyme B in the tumors determined by the flow cytometric assay.